S&P Futures
5,909.25 +3.25 (+0.06%) Dow Futures
43,549.00 +31.00 (+0.07%) Nasdaq Futures
20,489.50 +6.00 (+0.03%) Russell 2000 Futures
2,294.80 +3.60 (+0.16%) Crude Oil
69.59 +0.37 (+0.53%) Gold
2,746.60 +16.60 (+0.61%)
Adocia SA (ADOC.PA)
- Business Wire
ADOCIA Announces Patenting Stable Combinations of GLP-1 and Amylin Analogs for the Treatment of Obesity and Diabetes Using Its BioChaperone® Platform
LYON, France, October 15, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 - ADOC), a clinical-stage biopharmaceutical company specialized in the discovery and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announced today that it has filed patents of stable formulations of hormone combinations for the treatment of obesity and diabetes using its BioChaperone® platform.
- Business Wire
Number of Shares and Voting Rights of ADOCIA as of September 30th, 2024
LYON, France, October 08, 2024--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions
